Show simple item record

dc.creatorToledo,Victor
dc.creatorRamírez,Galia
dc.creatorValck,Carolina
dc.creatorLópez,Nandy
dc.creatorRibeiro,Carolina H
dc.creatorMaldonado,Ismael
dc.creatorAguilar,Lorena
dc.creatorLemus,David
dc.creatorFerreira,Arturo
dc.date2010-01-01
dc.date.accessioned2019-05-02T21:21:56Z
dc.date.available2019-05-02T21:21:56Z
dc.identifierhttps://scielo.conicyt.cl/scielo.php?script=sci_arttext&pid=S0716-97602010000300004
dc.identifier.urihttp://revistaschilenas.uchile.cl/handle/2250/82062
dc.descriptionAngiogenesis is a complex multi-step process of neovascularization arising from preexisting blood vessels whose generation is regulated by pro- and anti-angiogenic factors. Both Trypanosoma cruzi calreticulin (TcCRT) and its human counterpart (HuCRT) are antiangiogenic. This is the first report where the TcCRT and HuCRT anti-angiogenic properties are compared in vivo. In the chick embryonic chorioallantoid membrane assay (CAM) and at equimolar concentrations, TcCRT displayed significantly higher antiangiogenic activities than its human counterpart. LPS had marginal effects at the concentrations present in the recombinant protein preparations and the TcCRT antiangiogenic effects were largely inhibited by specific polyclonal antibodies, thus, reinforcing the fact that the observed TcCRT effects can be attributed to the parasite-derived molecule and not to the endotoxin. The antiangiogenic TcCRT effects correlate with its anti-tumor in vivo effects, as recently shown in our laboratory.
dc.formattext/html
dc.languageen
dc.publisherSociedad de Biología de Chile
dc.relation10.4067/S0716-97602010000300004
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourceBiological Research v.43 n.3 2010
dc.subjectCalreticulin
dc.subjectT. cruzi
dc.subjectanti-angiogenesis
dc.titleComparative in vivo antiangiogenic effects of calreticulin from Trypanosoma cruzi and Homo sapiens sapiens


This item appears in the following Collection(s)

Show simple item record